Article: A pharmacodynamic and pharmacokinetic comparison of pindolol 20 mg retard and a conventional tablet

In 10 healthy volunteers the time course of cardiac beta-adrenoceptor blocking activity, plasma levels and cumulative urinary excretion of pindolol were compared during a 4-day course of pindolol 5 mg (Visken) t. d. s., and one tablet of pindolol 20 mg retard (Visken retard) once a day. After oral administration of the 20 mg retard tablet, plasma concentrations of pindolol higher than half the maximum value (1/2 Cp (tmax)) were maintained about 2.5 times as long as after administration of the conventional 5 mg tablet. This is evidence for an important and marked retardation of drug release. During treatment with pindolol 20 mg retard once daily, cardiac beta-adrenoceptor blockade, measured by the reduction in exercise-induced tachycardia and in the exercise-induced rise in systolic blood pressure, at almost all times throughout the 24 h period was at least as great as during treatment with pindolol 5 mg t. d. s. This suggests that patients successfully treated with pindolol 5 mg t. d. s. can be maintained with the same beta-adrenoceptor blockade by a single tablet of pindolol 20 mg retard once daily.

Citing Articles

The role of 5-HT1a and 5-HT2a receptors in attention and motor control: a mechanistic study in healthy volunteers.

Wingen M, Kuypers K, Ramaekers J Psychopharmacology (Berl). 2006; 190(3):391-400.

PMID: 17124621 DOI: 10.1007/s00213-006-0614-x.

Risk assessment of adverse pulmonary effects induced by adrenaline beta-receptor antagonists and rational drug dosage regimen based on receptor occupancy.

Yamada Y, Matsuyama K, Ito K, Sawada Y, Iga T J Pharmacokinet Biopharm. 1995; 23(5):463-78.

PMID: 8656342 DOI: 10.1007/BF02353469.

Comparison of the effect of pindolol and propranolol on heart rate after acute and chronic administration.

Finch M, OConnor P, Harron D, Shanks R Br J Clin Pharmacol. 1983; 15(4):431-4.

PMID: 6849778 PMC: 1427788. DOI: 10.1111/j.1365-2125.1983.tb01526.x.

Pharmacokinetics and pharmacodynamics of conventional and controlled-release formulations of metipranolol in man.

Lapka R, Sechser T, REJHOLEC V, Peterkova M, Votavova M Eur J Clin Pharmacol. 1990; 38(3):243-7.

PMID: 1971217 DOI: 10.1007/BF00315024.

Does treatment with beta-adrenergic blocking agents cause a decrease in beta 2-adrenoceptor affinity?.

Blankesteijn W, Graafsma S, Hectors M, Olde Riekerink E, Rodrigues de Miranda J, Thien T Eur J Clin Pharmacol. 1992; 42(6):613-8.

PMID: 1352497 DOI: 10.1007/BF00265924.

References

1.

Lang E, Fitscha P, SCHIESS W . [Beta-blockader, pindolol, in the therapy of angina pectoris; a report on a multicentric controlled study]. Wien Med Wochenschr. 1979; 129(17):484-8. View

2.

Aellig W . beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers. Br J Clin Pharmacol. 1976; 3(2):251-7. PMC: 1428873. DOI: 10.1111/j.1365-2125.1976.tb00600.x. View

3.

PACHA W . A method for the fluorimetric determination of 4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB46), a beta-blocking agent, in plasma and urine. Experientia. 1969; 25(8):802-3. DOI: 10.1007/BF01897885. View

4.

Aellig W, Nuesch E, Pacha W . Pharmacokinetic comparison of pindolol 30 mg retard and 15 mg normal tablets. Eur J Clin Pharmacol. 1982; 21(6):451-5. DOI: 10.1007/BF00542037. View

5.

Rosenthal J, Kaiser H, HAMMERSCHMIDT D, Welzel D . [The practice of hypertensive therapy using a beta receptor blocker. A multicentric study using 15 mg Visken]. Med Welt. 1977; 28(48):1969-74. View

6.

Meier J, Nuesch E . Pindolol, a beta-adrenoceptor blocking agent with a negligible first-pass effect. Br J Clin Pharmacol. 1977; 4(3):371-2. PMC: 1429071. DOI: 10.1111/j.1365-2125.1977.tb00726.x. View

7.

Frithz G . Initiation of once-daily pindolol treatment. Br Med J. 1978; 1(6108):302. PMC: 1602693. DOI: 10.1136/bmj.1.6108.302-c. View

8.

Robinson B . Relation of heart rate and systolic blood pressure to the onset of pain in angina pectoris. Circulation. 1967; 35(6):1073-83. DOI: 10.1161/01.cir.35.6.1073. View

9.

Meier J . Beta-adrenoceptor-blocking agents: pharmacokinetic differences and their clinical implications illustrated on pindolol. Cardiology. 1979; 64 Suppl 1:1-13. View

10.

Aellig W . [Clinicopharmacological studies with pindolol following intravenous and oral administration]. Adv Clin Pharmacol. 1976; 11:9-13. View

11.

Aellig W . Comparison of the duration of action of pindolol and slow release oxprenolol in healthy volunteers. Eur J Clin Pharmacol. 1978; 14(3):167-9. DOI: 10.1007/BF02089955. View

12.

Gugler R, BODEM G . Single and multiple dose pharmacokinetics of pindolol. Eur J Clin Pharmacol. 1978; 13(1):13-6. DOI: 10.1007/BF00606675. View

13.

Meier J, Nuesch E, Schmidt R . Pharmacokinetic criteria for the evaluation of retard formulations. Eur J Clin Pharmacol. 1974; 7(6):429-32. DOI: 10.1007/BF00560355. View

A Pharmacodynamic and Pharmacokinetic Comparison of Pindolol 20 Mg Retard and a Conventional Tablet